Literature DB >> 16941543

A taxonomy of model structures for economic evaluation of health technologies.

Alan Brennan1, Stephen E Chick, Ruth Davies.   

Abstract

Models for the economic evaluation of health technologies provide valuable information to decision makers. The choice of model structure is rarely discussed in published studies and can affect the results produced. Many papers describe good modelling practice, but few describe how to choose from the many types of available models. This paper develops a new taxonomy of model structures. The horizontal axis of the taxonomy describes assumptions about the role of expected values, randomness, the heterogeneity of entities, and the degree of non-Markovian structure. Commonly used aggregate models, including decision trees and Markov models require large population numbers, homogeneous sub-groups and linear interactions. Individual models are more flexible, but may require replications with different random numbers to estimate expected values. The vertical axis of the taxonomy describes potential interactions between the individual actors, as well as how the interactions occur through time. Models using interactions, such as system dynamics, some Markov models, and discrete event simulation are fairly uncommon in the health economics but are necessary for modelling infectious diseases and systems with constrained resources. The paper provides guidance for choosing a model, based on key requirements, including output requirements, the population size, and system complexity. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16941543     DOI: 10.1002/hec.1148

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  125 in total

1.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  Resource planning for ambulance services in mass casualty incidents: a DES-based policy model.

Authors:  Marion S Rauner; Michaela M Schaffhauser-Linzatti; Helmut Niessner
Journal:  Health Care Manag Sci       Date:  2012-06-01

3.  An empirical comparison of Markov cohort modeling and discrete event simulation in a capacity-constrained health care setting.

Authors:  L B Standfield; T A Comans; P A Scuffham
Journal:  Eur J Health Econ       Date:  2015-12-29

Review 4.  Including adverse drug events in economic evaluations of anti-tumour necrosis factor-α drugs for adult rheumatoid arthritis: a systematic review of economic decision analytic models.

Authors:  Eleanor M Heather; Katherine Payne; Mark Harrison; Deborah P M Symmons
Journal:  Pharmacoeconomics       Date:  2014-02       Impact factor: 4.981

Review 5.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Authors:  Sun-Young Kim; Sue J Goldie
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 6.  Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.

Authors:  James E Stahl
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 7.  Economic evaluation of smoking-cessation therapies: a critical and systematic review of simulation models.

Authors:  Kristian Bolin
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

8.  Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.

Authors:  G Feljandro P Ramos; Antoinette D I van Asselt; Sandra Kuiper; Johan L Severens; Tanja Maas; Edward Dompeling; J André Knottnerus; Onno C P van Schayck
Journal:  Eur J Health Econ       Date:  2013-10-06

9.  Comparing three software tools for implementing markov models for health economic evaluations.

Authors:  Petra Menn; Rolf Holle
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Acknowledging patient heterogeneity in economic evaluation : a systematic literature review.

Authors:  Janneke P C Grutters; Mark Sculpher; Andrew H Briggs; Johan L Severens; Math J Candel; James E Stahl; Dirk De Ruysscher; Albert Boer; Bram L T Ramaekers; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.